Meeting
2023 ASCO Annual Meeting
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
Presenter
George Lau, MD, FRCP
Humanity and Health Clinical Trial Center, Humanity and Health Medical Group
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03298451
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4004)
DOI
10.1200/JCO.2023.41.16_suppl.4004
Abstract #
4004
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Speaker: Ghassan K. Abou-Alfa, MBA, MD
Videos & Slides
2022 ASCO Annual Meeting
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Speaker: Bruno Sangro, MD, PhD
Speaker: Manish A. Shah, MD
Videos & Slides
2024 ASCO Annual Meeting
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
Speaker: Stephen Lam Chan, MD, FRCP, MRCP